Surgical therapy for Barrett's esophagus: Prevention, protection and excision

Diseases of the Esophagus

Volumn 15, Issue 2, 2002, Pages 109-116

  DeMeester, T R ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OMEPRAZOLE; RANITIDINE;

ANTIREFLUX OPERATION; ARTICLE; BARRETT ESOPHAGUS; CANCER RISK; CLINICAL TRIAL; DYSPLASIA; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; EXCISION; GASTROESOPHAGEAL REFLUX; HEALING; HUMAN; INTESTINE METAPLASIA; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; SYMPTOM; YAG LASER;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; GASTROESOPHAGEAL REFLUX; HUMANS; METAPLASIA; MUCOUS MEMBRANE;

EID: 0036411715     PISSN: 11208694     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2050.2002.00217.x     Document Type: Article

References (48)

1. Hameeteman W, Tytgat G N, Houthoff H J, van den Tweel J G. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989; 96: 1249-1256.
2. Cameron A J, Ott B J, Payne W S. The incidence of adenocarcinoma in columnar lined (Barrett's) esophagus. New Engl J Med 1985; 313: 857-859.
3. Provenzale D, Kemp J A, Arora S, Wong J B. A guide for surveillance of patients with Barrett's esophagus. Am J Gastroenterol 1994; 89: 670-680.
4. Cameron A J, Lomboy C T. Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology 1992; 103: 1241-1245.
5. Clark G W, Ireland A P, Chandrasoma P, DeMeester T R, Peters J H, Bremner C G. Inflammation and metaplasia in the transitional epithelium of the gastroesophageal junction: a new marker for gastroesophageal reflux disease (Abstract). Gastroenterology 1994; 106: A63.
6. Spechler S J, Zeroogian J M, Antonioli D A, Wong H H, Goyal R K. Prevalence of metaplasia at the gastroesophageal junction. Lancet 1994; 344: 1533-1536.
7. Öberg S, Peters J H, DeMeester T R et al. Inflammation and specialized intestinal metaplasia of cardiac mucosa is a manifestation of gastroesophageal reflux disease. Ann Surg 1997; 226: 522-530.
8. Öberg S, DeMeester T R, Peters J H et al. The extent of Barrett's esophagus depends on the status of the lower esophageal sphincter and the degree of esophageal acid exposure. J Thorac Cardiovasc Surg 1999; 117: 572-580.
9. Sampliner R E. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1998; 93: 1028-1032.
10. Katzka D A, Castell D D. Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1994; 89: 989-991.
11. Sampliner R E. Effect of up to 3 years of high-dose lansoprazol on Barrett's esophagus. Am J Gastroenterol 1994; 89: 1844-1848.
12. Shaffer R, Francis J, Carrougher J, Kadakia S. Effect of omeprazole on Barrett's epithelium after 3 years of therapy. Gastroenterology 1996; 110: A255.
13. Ortiz A, Martinez de Haro L F, Parrilla P et al. Conservative treatment versus antireflux surgery in Barrett's esophagus: long-term results of a prospective study. Br J Surg 1996; 83: 274-278.
14. Sampliner R E, Garewal H S, Fennerty M B, Aikin M. Lack of impact of therapy on extent of Barrett's esophagus in 67 patients. Digestive Dis Sci 1990; 35: 93-96.
15. Sharma P, Morales T G, Bhattacharya A, Garewal H S, Sampliner R E. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow up. Am J Gastroenterol 1997; 92: 2012-2016.
16. Legergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. New Engl J Med 1999; 340: 825-831.
17. Stein H J, Kauer W K J, Feussner H, Siewert J R. Bile reflux in benign and malignant Barrett's esophagus: effect of medical acid suppression and Nissen fundoplication. J Gastrointest Surg 1998; 2: 333-341.
18. Spechler S J. Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans. The Department of Veterans Affairs Gastroesophageal Reflux Disease Study Group. New Engl J Med 1992; 326: 786-792.
19. DeMeester T R, Bonavina L, Albertucci M. Nissen fundoplication for gastroesophageal reflux disease: evaluation of primary repair in 100 consecutive patients. Ann Surg 1986; 204: 9-20.
20. Stein H J, Bremmer R M, Jamieson J, DeMeester T R. Effect of Nissen fundoplication on esophageal motor function. Arch Surg 1992; 127 (7): 788-791.
21. Peracchia A, Bancewicz J, Bonavina L et al. Fundoplication is an effective treatment for gastro-oesophageal reflux disease. Gastroenterol Intl 1995; 8 (1): 1-7.
22. Hinder R A, Filipi C J, Wetscher G, Neary P, DeMeester T R, Perdikis G. Laparoscopic Nissen fundoplication is an effective treatment for gastroesophageal reflux disease. Ann Surg 1994; 220 (4): 472-483.
23. Peters J H, DeMeester T R, Crookes P, Öberg S, de Vos Shoop H, Hagen J A, Bremner C G. The treatment of gastroesophageal reflux disease with Laparoscopic Nissen fundoplication. Ann Surg 1998; 228 (1): 40-50.
24. Luostarinen M, Isolauri J, Laitinen J et al. Fate of Nissen fundoplication after 20 years. A clinical endoscopical, and functional analysis. Gut 1993; 34: 1015-1020.
25. Thor K B, Silander T. A long-term randomized prospective trial of Nissen procedure versus a modified toupet technique. Ann Surg 1989; 210: 719-724.
26. Johansson J, Johansson F, Joelsson B, Floren C H, Walther B. Outcome 5 years after 360° fundoplication for gastroesophageal reflux disease. Br J Surg 1993; 80: 46-49.
27. Wetscher G, Profanter C, Gadenstätter M et al. Medical treatment of gastroesophageal reflux disease does not prevent the development of Barrett's metaplasia and poor esophageal body motility. Langenbeck Arch Chir 1997; 382: 95-99.
28. Brand D L, Ylviaakev J T, Gelfand M, Pope C E. Regression of columnar esophagus (Barrett's) epithelium after antireflux surgery. New Engl J Med 1980; 302: 844-848.
29. DeMeester S R, DeMeester T R. Columnar mucosa, intestinal metaplasia and adenocarcinoma of the esophagus and cardia: 50 years of controversy. Ann Surg 2002; 231: 303-321.
30. DeMeester S R, Campos G M, DeMeester T R, Bremner C G, Hagen J A, Peters J H, Crookes P F. The impact of an antireflux procedure on intestinal metaplasia of the cardia. Ann Surg 1998; 228: 547-556.
31. Low D S, Levine D S, Dail D H, Kozarek R A. Histology and anatomic changes in Barrett's esophagus after antireflux surgery. Am J Gastroenterol 1999; 94: 80-85.
32. Salo J A, Salminen J T, Kiviluoto T A et al. Treatment of Barrett's esophagus by endoscopic laser ablation and antireflux surgery. Ann Surg 1998; 227: 40-44.
33. McCallum R, Polepalle S, Davenport K, Frierson H, Boyd S. Role of antireflux surgery against dysplasia in Barrett's esophagus. Gastroenterology 1991; 100: A121.
34. Katz D, Rothstein R, Schmed A, Dunn J, Seaver K, Antonioli D. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus. Am J Gastroenterol 1998; 93: 536-541.
35. McDonald M L, Trastek V F, Allen M S, Deschamps C, Pairolero P C. Barrett's esophagus: Does an antireflux procedure reduce the need for endoscopic surveillance? J Thorac Cardiovasc Surg 1996; 111: 1135-1138.
36. Riddell R H, Goldman H, Ransohoff D F et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Human Pathol 1983; 14 (11): 931-968.
37. Schmidt H G, Riddell R H, Walther B, Skinner D B, Riemann J F. Dysplasia in Barrett's esophagus. J Cancer Res Clin Oncol 1985; 110 (2): 145-152.
38. Reid B J, Haggitt R C, Rubin C E et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 1988; 19: 166-178.
39. Streitz J M, Jr, Andrews C W, Jr, Ellis F H, Jr. Endoscopic surveillance of Barrett's esophagus. Does it help? J Thorac Cardiovasc Surg 1993; 105 (3): 383-387, Discussion 387-388.
40. Peters J H, Clark G W, Ireland A P, Chandrasoma P, Smyrk T C, DeMeester T R. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 1994; 108: 813-821, Discussion 821-822.
41. Heitmiller R F, Redmond M, Hamilton S R. Barrett's esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy. Ann Surg 1996; 224: 66-71.
42. Clark G W, Dreuw B, Burdiles P. The importance of endoscopic surveillance in the detection of early Barrett's adenocarcinoma. Gastroenterology 1993; 104: 392.
43. Salo J A, Salminen J T, Kiviluoto T A et al. Treatment of Barrett's esophagus by endoscopic laser ablation and antireflux surgery. Ann Surg 1998; 227: 40-44.
44. Levine M S, Carolione D, Thompson J J, Kressel H Y, Laufer I, Herlinger H. Adenocarcinoma of the esophagus: relationship to Barrett mucosa. Radiology 1984; 150 (2): 305-309.
45. Spechler S J, Goyal R K. Cancer surveillance in Barrett's esophagus: what is the end point? Gastroenterology 1994; 106 (1): 275-277.
46. Cameron A J, Carpenter H C, Trastek V F. Barrett's esophagus with high grade dysplasia: is resection required? Gastroenterology 1997; 106: 375.
47. Nigro J J, Hagen J A, DeMeester T R, DeMeester S R, Theisen J, Peters J H, Kiyabu M. Occult esophageal adenocarcinoma: extent of disease and implications for effective therapy. Ann Surg 1999; 230 (3): 433-440.
48. Overholt B F, Panjehpour M, Haydek J M. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. Gastrointest Endo 1999; 49: 1-7.